{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:47:05Z","timestamp":1794559625396,"version":"4.9.1"},"reference-count":29,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,3,31]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Addition of bevacizumab and paclitaxel as induction therapy prior to standard atezolizumab and nab-paclitaxel in patients with programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) may help to overcome vascular endothelial growth factor-associated resistance mechanisms that limit the immune-mediated antitumour efficacy of atezolizumab and nab-paclitaxel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+TNBC (INDUCE) study is a multicentre, randomised, open-label, phase II trial designed to evaluate the efficacy and safety of two cycles of induction therapy with bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel compared with standard atezolizumab and nab-paclitaxel in patients with PD-L1-positive mTNBC. The primary outcome of the study is progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumours, V.1.1. We have estimated that 89 PFS events are needed to allow a power of 80% to detect a difference between treatment groups at a one-sided significance level of 10% in this study. The target sample size is set to 106 patients to account for dropouts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol and informed consent form have been approved by the Certified Research Review Board at the Nagoya University Graduate School of Medicine, Nagoya, Japan. Study results will be presented at international conferences and published in a peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      jRCTs041240039\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06793553\">NCT06793553<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098088","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:25:24Z","timestamp":1778682324000},"page":"e098088","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06793553","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8064-648X","authenticated-orcid":false,"given":"Yukinori","family":"Ozaki","sequence":"first","affiliation":[{"name":"Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Immunogenomic Medicine, Research Institute, National Cancer Center, Tokyo, Japan"},{"name":"Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan"},{"name":"Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Department of General Surgery (Breast and Endocrine Groups), Tohoku University Hospital, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Tokuda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-8575","authenticated-orcid":false,"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Division of Cancer Immunology, Research Institute, National Cancer Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8647-5098","authenticated-orcid":false,"given":"Nobuhiro","family":"Shibata","sequence":"additional","affiliation":[{"name":"Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan"},{"name":"Department of Clinical Oncology, Kansai Medical University Hospital, Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Osaka University Hospital, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic and Breast Surgery, Ehime University Hospital, Toon, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Naha Nishi Clinic, Naha, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Miwa","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan"},{"name":"Division of Cancer Immunology, Research Institute, National Cancer Center, Tokyo, Japan"},{"name":"Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Division of Cancer Immune Multicellular System Regulation, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":false,"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026051307251632000_16.5.e098088.1","doi-asserted-by":"crossref","first-page":"11782234231203292","DOI":"10.1177\/11782234231203292","article-title":"Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer","volume":"17","author":"Celik","year":"2023","journal-title":"Breast Cancer (Auckl)"},{"key":"2026051307251632000_16.5.e098088.2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026051307251632000_16.5.e098088.3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101791","article-title":"Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis","volume":"16","author":"Kesireddy","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026051307251632000_16.5.e098088.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"2026051307251632000_16.5.e098088.5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809615"},{"key":"2026051307251632000_16.5.e098088.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101541","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"8","author":"Im","year":"2023","journal-title":"ESMO Open"},{"key":"2026051307251632000_16.5.e098088.7","unstructured":"Roche Registration GmbH . Atezolizumab: summary of product characteristics, 2024. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecentriq-epar-product-information_en.pdf [Accessed 15 Nov 2024]."},{"key":"2026051307251632000_16.5.e098088.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1685-x"},{"key":"2026051307251632000_16.5.e098088.9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","article-title":"Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation","volume":"70","author":"Miles","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026051307251632000_16.5.e098088.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"2026051307251632000_16.5.e098088.11","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01138-4"},{"key":"2026051307251632000_16.5.e098088.12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.2021.39.15_suppl.1006","article-title":"The tumor microenvironment (TME) and atezolizumab + nab -paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130","volume":"39","author":"Emens","year":"2021","journal-title":"JCO"},{"key":"2026051307251632000_16.5.e098088.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.002"},{"key":"2026051307251632000_16.5.e098088.14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2019","journal-title":"Med Oncol"},{"key":"2026051307251632000_16.5.e098088.15","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000327"},{"key":"2026051307251632000_16.5.e098088.16","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y"},{"key":"2026051307251632000_16.5.e098088.17","doi-asserted-by":"publisher","DOI":"10.7150\/jca.44313"},{"key":"2026051307251632000_16.5.e098088.18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603678"},{"key":"2026051307251632000_16.5.e098088.19","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506"},{"key":"2026051307251632000_16.5.e098088.20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2325"},{"key":"2026051307251632000_16.5.e098088.21","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V"},{"key":"2026051307251632000_16.5.e098088.22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0325"},{"key":"2026051307251632000_16.5.e098088.23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.03081","article-title":"Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer","volume":"9","author":"Georganaki","year":"2018","journal-title":"Front Immunol"},{"key":"2026051307251632000_16.5.e098088.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01023","article-title":"Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors","volume":"10","author":"de Aguiar","year":"2019","journal-title":"Front Immunol"},{"key":"2026051307251632000_16.5.e098088.25","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1158\/1538-7445.SABCS20-PS4-14","article-title":"Abstract PS4-14: Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2-negative MBC in NEWBEAT trial (WJOG9917BTR)","volume":"81","author":"Ozaki","year":"2021","journal-title":"Cancer Res"},{"key":"2026051307251632000_16.5.e098088.26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2022.05.014","article-title":"Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: primary results and biomarker data from a phase 2 trial (WJOG9917B)","volume":"171","author":"Ozaki","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026051307251632000_16.5.e098088.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"2026051307251632000_16.5.e098088.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2026051307251632000_16.5.e098088.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:25:30Z","timestamp":1778682330000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2024-098088"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098088","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098088.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098088.supp2","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}